Boston Scientific (BSX) Reports In-Line Q2 EPS; Bumps FY16 Rev View

Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.27, in-line with the analyst estimate of $0.27. Revenue for the quarter came in at $2.13 billion versus the consensus estimate of $2.05 billion.

"Our strong performance is evidence of the success of our category leadership strategy," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "Our deep portfolio, commitment to innovation and high-performance culture are helping us meet the needs of our customers and patients while sustaining growth and momentum."

GUIDANCE:

Boston Scientific sees Q3 2016 EPS of $0.25-$0.27, versus the consensus of $0.27. Boston Scientific sees Q3 2016 revenue of $2.035-2.085 billion, versus the consensus of $2.04 billion.

Boston Scientific sees FY2016 EPS of $1.07-$1.11, versus the consensus of $1.09. Boston Scientific sees FY2016 revenue of $8.27-8.37 billion, versus prior guidance of $8.075-8.225 billion and the consensus of $8.17 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance